←
Therapeutic Advances in Infectious Disease1,533 posts
Therapeutic Advances in Infectious Disease avatar

Therapeutic Advances in Infectious Disease

@TAInfDis

A SAGE Open Access journal | Publishing high-quality articles in infectious disease | Editor-in-Chief @andhen25 | IF 3.8

◷ Joined February 2020▧ 163 Photos and videos
Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Nov 14

Unaccompanied asylum-seeking children and young people face increased HBV risk, yet vaccination uptake remains low. This UK service evaluation found that only 23% had documented HBV vaccination despite 92% receiving recommendations. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Nov 12

Cutaneous leishmaniasis in infants is rare, and treatment options are limited. This case highlights severe hematologic toxicity associated with sodium stibogluconate, underscoring the need for safer, evidence-based therapies in this vulnerable population journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Nov 10

🍄 AI is transforming medical mycology, enabling automated fungal identification, image analysis, and clinical diagnostics. Read more here- journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Nov 10

🌍 Systematic review found a 15% pooled prevalence of toxigenic C. diff among patients with diarrhea, with substantial geographic variation and continued circulation of hypervirulent strains. Vancomycin and fidaxomicin resistance remained low. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 31

Same drugs. Same regimen. Different outcomes. Why? TB treatment response is shaped by a complex interplay of host factors, drug exposure, lesion microenvironments, and pathogen characteristics. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 29

Aminoglycoside dosing in CF remains challenging. 🎯 Cmax target achieved in 50% of amikacin courses 🎯 Target achieved in 0% of gentamicin courses 📈 Most patients improved clinically journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 28

-E. faecalis endocarditis: ampicillin + ceftriaxone -VRE E. faecium: β-lactam + high-dose dapto may help - Uncomplicated bacteremia: limited benefit of combo Evidence, clinical implications of adjunctive β-lactams: journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 19

🦠 When standard antifungals fail, what are the options? A challenging case of multidrug-resistant Candida auris osteomyelitis highlights the potential role of fosmanogepix alongside aggressive surgical source control. journals.sagepub.com/doi/10.…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 13

🦠 Pseudomonas aeruginosa UTIs in Palestine: In a 190-patient cohort, mortality was 11.6%. Immunocompromised status & meropenem resistance were independent predictors of mortality, highlighting early risk recognition and appropriate antimicrobial therapy. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 13

Often mistaken for TB, Histoplasma can affect immunocompetent and immunocompromised patients. This review highlights critical diagnostic gaps, and proposes a pragmatic testing pathway while outlining priorities for future research. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Oct 13

Candida tropicalis spondylodiscitis: a rare, indolent infection that can be easily missed. Persistent fever and elevated β-D-glucan should prompt consideration of an occult fungal focus. journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Sep 26

In hospitalized children with LRTIs, multiplex RT-qPCR detected ≥1 pathogen in 78.5%. Viral-only detection was most common (40.9%), while viral–bacterial co-detection occurred in 26%. Importantly, detection ≠ causation, journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Sep 25

TB stigma remains a major barrier to TB control. In this study of 385 patients in Napak district, Uganda, 43.1% reported high perceived stigma. Poor TB knowledge, inadequate social support, and secondary education were associated with higher stigma journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Sep 24

Mining may be an important occupational risk factor for TB. In a case-control study from Ethiopia (n=735), miners had >3× higher odds of active pulmonary TB (AOR 3.51, 95% CI 1.89–6.50). journals.sagepub.com/doi/ful…

Therapeutic Advances in Infectious Disease avatar
Therapeutic Advances in Infectious Disease@TAInfDis·Sep 18

New modeling data on RSV prevention in infants: seasonal clesrovimab, particularly with catch-up, was projected to reduce RSV-LRTIs and healthcare costs compared with palivizumab, nirsevimab, and maternal vaccination. journals.sagepub.com/doi/ful…